| Literature DB >> 29844124 |
Jing Meng1, Shuang Chen2, Jing-Xia Han1, Baoxin Qian3, Xiao-Rui Wang4, Wei-Long Zhong1, Yuan Qin1, Heng Zhang1, Wan-Feng Gao1,2, Yue-Yang Lei1,2, Wei Yang2, Lan Yang2, Chao Zhang1,2, Hui-Juan Liu2,4, Yan-Rong Liu2, Hong-Gang Zhou1, Tao Sun5,2, Cheng Yang5,2.
Abstract
Twist is a critical epithelial-mesenchymal transition (EMT)-inducing transcription factor that increases expression of vimentin. How Twist1 regulates this expression remains unclear. Here, we report that Twist1 regulates Cullin2 (Cul2) circular RNA to increase expression of vimentin in EMT. Twist1 bound the Cul2 promoter to activate its transcription and to selectively promote expression of Cul2 circular RNA (circ-10720), but not mRNA. circ-10720 positively correlated with Twist1, tumor malignance, and poor prognosis in hepatocellular carcinoma (HCC). Twist1 promoted vimentin expression by increasing levels of circ-10720, which can absorb miRNAs that target vimentin. circ-10720 knockdown counteracted the tumor-promoting activity of Twist1 in vitro and in patient-derived xenograft and diethylnitrosamine-induced TetOn-Twist1 transgenic mouse HCC models. These data unveil a mechanism by which Twist1 regulates vimentin during EMT. They also provide potential therapeutic targets for HCC treatment and provide new insight for circular RNA (circRNA)-based diagnostic and therapeutic strategies.Significance: A circRNA-based mechanism drives Twist1-mediated regulation of vimentin during EMT and provides potential therapeutic targets for treatment of HCC.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4150/F1.large.jpg Cancer Res; 78(15); 4150-62. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29844124 DOI: 10.1158/0008-5472.CAN-17-3009
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701